Cross-sectional study examines time to market launch for therapeutics in most-favored-nation settings, suggesting implications for pricing benchmarks.
This cross-sectional study examines the time to market launch for recently approved therapeutics likely eligible for 2 new mandatory service and delivery models in most-favored-nation countries following US launch.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: